Completed PHASE4 INTERVENTIONAL 2-arm NCT00663052

Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis (PRISTINE)

A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis

Sponsor: Pfizer

Conditions Plaque Psoriasis Psoriasis

Interventions Etanercept

Updated 8 times since 2017 Last updated: Mar 29, 2012 Started: Jun 30, 2008 Primary completion: Jan 31, 2010 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Plaque Psoriasis and Psoriasis, this trial is completed. The trial is conducted by Pfizer and has accumulated 8 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Mar 2022 — Jul 2024 [monthly]

Completed PHASE4
Jan 2022 — Mar 2022 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jan 2021 — Jan 2022 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, Greece , Bangkok, Thailand , Barcelona, Spain , Bochum, Germany , Brussels, Belgium , Budapest, Hungary , Capital Federal, Argentina , Catanzaro, Italy , Debrecen, Hungary , Erlangen, Germany and 25 more locations